vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and CSW INDUSTRIALS, INC. (CSW). Click either name above to swap in a different company.
CSW INDUSTRIALS, INC. is the larger business by last-quarter revenue ($233.0M vs $183.1M, roughly 1.3× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 4.4%, a 8.9% gap on every dollar of revenue. On growth, CSW INDUSTRIALS, INC. posted the faster year-over-year revenue change (20.3% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $22.7M). Over the past eight quarters, CSW INDUSTRIALS, INC.'s revenue compounded faster (5.1% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AMPH vs CSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $233.0M |
| Net Profit | $24.4M | $10.3M |
| Gross Margin | 46.8% | 39.7% |
| Operating Margin | 19.4% | 7.4% |
| Net Margin | 13.3% | 4.4% |
| Revenue YoY | -1.8% | 20.3% |
| Net Profit YoY | -35.7% | -61.9% |
| EPS (diluted) | $0.51 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $233.0M | ||
| Q3 25 | $191.8M | $277.0M | ||
| Q2 25 | $174.4M | $263.6M | ||
| Q1 25 | $170.5M | $230.5M | ||
| Q4 24 | $186.5M | $193.6M | ||
| Q3 24 | $191.2M | $227.9M | ||
| Q2 24 | $182.4M | $226.2M | ||
| Q1 24 | $171.8M | $210.9M |
| Q4 25 | $24.4M | $10.3M | ||
| Q3 25 | $17.4M | $40.7M | ||
| Q2 25 | $31.0M | $40.9M | ||
| Q1 25 | $25.3M | $35.1M | ||
| Q4 24 | $38.0M | $26.9M | ||
| Q3 24 | $40.4M | $36.1M | ||
| Q2 24 | $37.9M | $38.6M | ||
| Q1 24 | $43.2M | $31.8M |
| Q4 25 | 46.8% | 39.7% | ||
| Q3 25 | 51.4% | 43.0% | ||
| Q2 25 | 49.6% | 43.8% | ||
| Q1 25 | 50.0% | 44.2% | ||
| Q4 24 | 46.5% | 41.4% | ||
| Q3 24 | 53.3% | 45.6% | ||
| Q2 24 | 52.2% | 47.5% | ||
| Q1 24 | 52.4% | 44.4% |
| Q4 25 | 19.4% | 7.4% | ||
| Q3 25 | 13.2% | 20.5% | ||
| Q2 25 | 24.2% | 20.8% | ||
| Q1 25 | 21.9% | 19.5% | ||
| Q4 24 | 24.2% | 15.3% | ||
| Q3 24 | 29.8% | 22.6% | ||
| Q2 24 | 30.3% | 24.3% | ||
| Q1 24 | 27.9% | 21.0% |
| Q4 25 | 13.3% | 4.4% | ||
| Q3 25 | 9.0% | 14.7% | ||
| Q2 25 | 17.8% | 15.5% | ||
| Q1 25 | 14.8% | 15.2% | ||
| Q4 24 | 20.4% | 13.9% | ||
| Q3 24 | 21.1% | 15.8% | ||
| Q2 24 | 20.8% | 17.1% | ||
| Q1 24 | 25.1% | 15.1% |
| Q4 25 | $0.51 | $0.62 | ||
| Q3 25 | $0.37 | $2.41 | ||
| Q2 25 | $0.64 | $2.43 | ||
| Q1 25 | $0.51 | $2.05 | ||
| Q4 24 | $0.74 | $1.60 | ||
| Q3 24 | $0.78 | $2.26 | ||
| Q2 24 | $0.73 | $2.47 | ||
| Q1 24 | $0.81 | $2.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $40.2M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $1.1B |
| Total Assets | $1.6B | $2.3B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $40.2M | ||
| Q3 25 | $276.2M | $31.5M | ||
| Q2 25 | $231.8M | $38.0M | ||
| Q1 25 | $236.9M | $225.8M | ||
| Q4 24 | $221.6M | $213.8M | ||
| Q3 24 | $250.5M | $273.2M | ||
| Q2 24 | $217.8M | $18.9M | ||
| Q1 24 | $289.6M | $22.2M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | $800.1M | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | $166.0M |
| Q4 25 | $788.8M | $1.1B | ||
| Q3 25 | $776.7M | $1.1B | ||
| Q2 25 | $757.5M | $1.1B | ||
| Q1 25 | $751.3M | $1.1B | ||
| Q4 24 | $732.3M | $1.0B | ||
| Q3 24 | $727.7M | $1.0B | ||
| Q2 24 | $713.3M | $650.2M | ||
| Q1 24 | $672.4M | $615.7M |
| Q4 25 | $1.6B | $2.3B | ||
| Q3 25 | $1.7B | $1.5B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.4B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.6B | $1.0B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | 0.75× | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $28.9M |
| Free Cash FlowOCF − Capex | $24.6M | $22.7M |
| FCF MarginFCF / Revenue | 13.4% | 9.8% |
| Capex IntensityCapex / Revenue | 4.5% | 2.6% |
| Cash ConversionOCF / Net Profit | 1.35× | 2.81× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $162.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $28.9M | ||
| Q3 25 | $52.6M | $61.8M | ||
| Q2 25 | $35.6M | $60.6M | ||
| Q1 25 | $35.1M | $27.3M | ||
| Q4 24 | $29.0M | $11.6M | ||
| Q3 24 | $60.0M | $66.8M | ||
| Q2 24 | $69.1M | $62.7M | ||
| Q1 24 | $55.3M | $22.4M |
| Q4 25 | $24.6M | $22.7M | ||
| Q3 25 | $47.2M | $58.7M | ||
| Q2 25 | $25.0M | $57.7M | ||
| Q1 25 | $24.4M | $22.8M | ||
| Q4 24 | $16.6M | $8.5M | ||
| Q3 24 | $46.2M | $61.3M | ||
| Q2 24 | $63.1M | $59.6M | ||
| Q1 24 | $46.5M | $17.5M |
| Q4 25 | 13.4% | 9.8% | ||
| Q3 25 | 24.6% | 21.2% | ||
| Q2 25 | 14.3% | 21.9% | ||
| Q1 25 | 14.3% | 9.9% | ||
| Q4 24 | 8.9% | 4.4% | ||
| Q3 24 | 24.1% | 26.9% | ||
| Q2 24 | 34.6% | 26.3% | ||
| Q1 24 | 27.1% | 8.3% |
| Q4 25 | 4.5% | 2.6% | ||
| Q3 25 | 2.8% | 1.1% | ||
| Q2 25 | 6.1% | 1.1% | ||
| Q1 25 | 6.3% | 2.0% | ||
| Q4 24 | 6.7% | 1.6% | ||
| Q3 24 | 7.2% | 2.4% | ||
| Q2 24 | 3.3% | 1.4% | ||
| Q1 24 | 5.1% | 2.3% |
| Q4 25 | 1.35× | 2.81× | ||
| Q3 25 | 3.03× | 1.52× | ||
| Q2 25 | 1.15× | 1.48× | ||
| Q1 25 | 1.39× | 0.78× | ||
| Q4 24 | 0.76× | 0.43× | ||
| Q3 24 | 1.48× | 1.85× | ||
| Q2 24 | 1.82× | 1.62× | ||
| Q1 24 | 1.28× | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
